SDF1-CXCR4 antagonist AMD3100 progress in applied research.docVIP

 PAGE \* MERGEFORMAT 18 SDF1/CXCR4 antagonist AMD3100 progress in applied research [Abstract] AMD3100 is a stromal cell derived factor 1 (SDF 1) receptor CXCR4 antagonist, can effectively block the physiological functions of SDF 1/CXCR4 axis; SDF 1/CXCR4 axis involvement stem cell mobilization, migration, homing, embryo development, immune regulation, inflammation, autoimmune diseases, HIV infection, the growth of tumor cells play an important role in migration and so on. AMD3100 to quickly and efficiently mobilize hematopoietic stem cells and mesenchymal stem cells, inhibit tumor cell growth and metastasis, resistance off infected T lymphocytes in HIV 1 binding site, inhibition of certain inflammatory and autoimmune disease progression. so the AMD3100-depth study will help clinicians safe and effective mobilization of stem cells to repair damaged tissue, clinical treatment of HIV can 1 infection and certain tumors provide a new way. This paper reviews the progress of AMD3100 applied research. [Keywords:] AMD3100; SDF 1; CXCR4; mobilization; review literature AMD3100 (trade name Plerixafor) is a stromal cell derived factor 1 (SDF 1) non-peptide CXCR4 receptor blocker, derived from human studies of AMD3100 its anti-inflammatory effect of HIV 1, then by studying its anti-people Mechanism of HIV 1 infection and found that CXCR4 with AMD3100 could specifically block the SDF 1/CXCR4 axis of the physiological processes involved, which studies human AMD3100 has entered a new phase. There is now able to quickly and efficiently find AMD3100 mobilization of hematopoietic stem / progenitor cells [1], involved in HIV infection in T cells and inhibit tumor cell proliferation and migration, inflammation, rheumatoid arthritis and asthma, and other aspects important role. In this paper, AMD3100 past 10 years, progress in applied research reviewed below. 1 AMD3100 basis of the biological role SDF 1 is a CXC chemokine subfamily, was named as CXCL12, highly conserv